Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising novel therapeutic approach. However, primary and secondary resistance to CAR-T cell therapy is commonly encountered in various clinical trials. Despite the comprehensive studies to elucidate the mechanisms of resistance, effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Li, Li, Qing, Yan, Zi-Xun, Sheng, Ling-Shuang, Fu, Di, Xu, Pengpeng, Wang, Li, Zhao, Wei-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307822/
https://www.ncbi.nlm.nih.gov/pubmed/35869100
http://dx.doi.org/10.1038/s41598-022-16616-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307822/
https://www.ncbi.nlm.nih.gov/pubmed/35869100
http://dx.doi.org/10.1038/s41598-022-16616-2

Ejemplares similares